Acute upper limb ischemia in a patient with newly diagnosed paroxysmal atrial fibrillation
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Acute limb ischemia (ALI) due to an embolism is associated with high mortality rate and poor prognosis, and early diagnosis with prompt revascularization is required to reduce the risk of limb amputation or even death. The etiologies of ALI are diverse, and it includes an embolism from the heart and thrombotic occlusion of the atherosclerotic native vessels, stents, or grafts. An uncommon cause of ALI is acute arterial thromboembolism, and atrial fibrillation (AF) is the single most important risk factors for systemic thromboembolism. It is important to correctly identify the source of ALI for secondary prevention, as it depends on the underlying cause. Percutaneous transluminal angioplasty (PTA) has been proven to be a safe and effective treatment for focal atherosclerotic and thrombotic occlusive diseases of the aorta and its major extremity branches. Herein, we report on a 77-year-old female patient with acute upper limb ischemia, treated by PTA using a catheter-guided thrombectomy. He was newly diagnosed with paroxysmal AF (PAF) while evaluation the cause of his acute arterial thromboembolism. We recommend that cardiologists always consider PAF as a possible diagnosis even in patients without any history of AF under ALI because it is possible to develop thromboembolism in clinical practice
Abstract
Acute limb ischemia (ALI) due to an embolism is associated with high mortality rate and poor prognosis, and early diagnosis with prompt revascularization is required to reduce the risk of limb amputation or even death. The etiologies of ALI are diverse, and it includes an embolism from the heart and thrombotic occlusion of the atherosclerotic native vessels, stents, or grafts. An uncommon cause of ALI is acute arterial thromboembolism, and atrial fibrillation (AF) is the single most important risk factors for systemic thromboembolism. It is important to correctly identify the source of ALI for secondary prevention, as it depends on the underlying cause. Percutaneous transluminal angioplasty (PTA) has been proven to be a safe and effective treatment for focal atherosclerotic and thrombotic occlusive diseases of the aorta and its major extremity branches. Herein, we report on a 77-year-old female patient with acute upper limb ischemia, treated by PTA using a catheter-guided thrombectomy. He was newly diagnosed with paroxysmal AF (PAF) while evaluation the cause of his acute arterial thromboembolism. We recommend that cardiologists always consider PAF as a possible diagnosis even in patients without any history of AF under ALI because it is possible to develop thromboembolism in clinical practice
참고문헌 (13)
- Norgren L, "Inter-society consensus for the management of peripheral arterial disease (TASC II)", J Vasc Surg, 45, pp.S5~S67 (2007)
- Creager MA, "Clinical practice. Acute limb ischemia", N Engl J Med, 366, pp.2198~2206 (2012)
- Fuster V, "ACC", AHA, American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society, pp.Circulation, 2006[DOI]
- Nieuwlaat R, "Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation", Eur Heart J, 29, pp.1181~1189 (2008)
- Andersen LV, "Upper limb arterial thromboembolism: a systematic review on incidence, risk factors, and prognosis, including a meta-analysis of risk-modifying drugs", J Thromb Haemost, 11, pp.836~844 (2013)
- Andersen LV, "Upper-limb thrombo-embolectomy: national cohort study in Denmark", Eur J Vasc Endovasc Surg, 40, pp.628~634 (2010)
- Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
- Connolly SJ, "Apixaban in patients with atrial fibrillation", N Engl J Med, 364, pp.806~817 (2011)
- Ganesan AN, "The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding:a systematic review and meta-analysis", Eur Heart J, 37, pp.1591~1602 (2016)
- Hart RG, "Stroke with intermittent atrial fibrillation:incidence and predictors during aspirin therapy", J Am Coll Cardiol, 35, pp.183~187 (2000)
- Hohnloser SH, "Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy", J Am Coll Cardiol, 50, pp.2156~2161 (2007)
- Andersen LV, "Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation:a meta-analysis", Heart, 94, pp.1607~1613 (2008)
- Geller BJ, "Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial", Am Heart J, 170, pp.669~674 (2015)